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Abstract Dysregulation of B cell receptor (BCR) signalling is
a hallmark of chronic lymphocytic leukaemia (CLL) patholo-
gy, and targeting BCR pathway kinases has brought great ther-
apeutic advances. Activation of the BCR in lymphoid organs
has been associated with CLL cell proliferation and survival,
leading to progressive disease. While these responses are me-
diated predominantly by IgM, the role of IgD is less clear.
Seeking to uncover downstream consequences of individual
and combined stimulation of the two BCR isotypes, we found
an amplification of IgD expression and IgD-mediated calcium
signalling by previous stimulation of IgM in CLL. Furthermore,
no heterologous downmodulation of the isotypes, as observed
in healthy donors, was present. Only marginal downregulation
of the expression of various chemokine receptors byα-IgM and
α-IgD stimulation was found as compared to normal B cells.
Consistently, calcium responses of CLL cells to different
chemokines were only weakly affected by preceding BCR ac-
tivation. In contrast, migration towards the two homeostatic
chemokines CXCL12 and CCL21 was differentially regulated
by IgM and IgD. While IgM activation reduced migration of
CLL cells towards CXCL12, but not CCL21, IgD activation
predominantly impacted on CCL21 but not CXCL12-mediated
chemotaxis. This indicates that the preference for one chemo-
kine over the other may depend on the functional presence of
the two isotypes in CLL. Inhibitors against the kinases Syk,
Lyn, and Btk antagonised both BCR- and chemokine-induced
calcium signals.
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Introduction
Chronic lymphocytic leukaemia (CLL) is characterised by the
progressive accumulation of malignant monoclonal B lym-
phocytes in blood and primary and secondary lymphoid or-
gans. CLL cells are phenotypically mature B cells [1] usually
expressing both IgM and IgD on their surface. CLL cells dis-
play various degrees of anergy, linked to reduced IgM expres-
sion and signalling capacity [2, 3]. High B cell receptor (BCR)
signalling capacity in response to IgM [4] as well as IgD [5]
stimulation has been associated with adverse prognosis and
progressive disease. However, little is known about the func-
tional differences between these two isotypes, and their com-
bined role in CLL.
The importance of antigen stimulation for CLL is further
supported by the biased IGHV gene usage in CLL [6, 7].
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BCR and chemokine responses upon anti-IgM
and anti-IgD stimulation in chronic lymphocytic leukaemia
Unmutated CLL (u-CLL) tend to express low affinity poly-
and autoreactive BCRs, while high affinity monoreactive
BCRs occur mainly in mutated CLL (m-CLL) and have been
shown in certain cases to be specific for bacterial [8] or fungal
pathogens [9, 10]. Autonomous BCR signalling was de-
scribed as a hallmark of CLL [11]. Recently, on a basis of
transgenic murine CLLmodels, it was suggested that both cell
autonomous and cell external low affinity BCR interactions
contribute to CLL pathogenesis [12]. This obvious reliance of
CLL cells on both ligand-dependent and ligand-independent
BCR signals has led to the establishment of inhibitors against
BCR pathway kinases, targeting Syk, Btk and Lyn for CLL
treatment, with great clinical success [13–16]. A prominent
effect of Ibrutinib and other inhibitors in vivo is a lymphocy-
tosis caused by the redistribution of CLL cells from lymphoid
organs into the periphery [17], based on antagonisation of
migration and retention signals [18]. Consistently,
chemokine-mediated migration and integrin activation of
CLL cells were efficiently inhibited in vitro by targeting Syk
[19, 20] and Btk [21]. Collectively, this indicates that the ef-
fectiveness of these novel agents is, at least in part, due to a
block in the interaction of CLL cells with protective signals
from their direct lymphoidmicroenvironment. The chemokine
receptor CXCR4 and its ligand CXCL12 are of particular
significance for CLL cell migration and survival [22].
CXCL12 stimulation leads to phosphorylation of Syk [19]
and Btk [23]. Other chemokine receptors robustly expressed
on CLL cells are CXCR5, CCR7, and the atypical chemokine
receptor CCRL2, a presumed regulator of CCR7 activity [24].
Furthermore, CXCR3 is expressed on CLL in variable
amounts, in contrast to other B cell lymphomas. High
CXCR3 expression levels are associated with indolent dis-
ease, exerting a negative functional regulation on CXCR4
[25]. In healthy B cells, activation of the BCR fundamentally
alters the expression and function of CXCR4 [26], CCR7, and
CXCR5 [27]. In CLL, downregulation of CXCR4 [28] and
CXCR5 [29] was observed predominantly in high-risk cases
after stimulation with immobilised α-IgM antibodies. In con-
trast, the impact of IgD activation on the expression pattern of
these receptors has not been evaluated yet.
In this study, we examined how IgM and IgD cross-
respond to stimulation in CLL and how BCR stimulation im-
pacts on chemokine receptor expression and function, also in
the context of therapeutic BCR inhibition.
Material and methods
Patient samples and cell isolation
Blood samples were collected from CLL patients after in-
formed consent and ethical approval at the Freiburg Medical
University Center and the Third Medical Department,
Paracelsus Medical University Salzburg. The samples collect-
ed in Salzburg were used for the chemotaxis assays during
revision of the manuscript; for all other experiments, the
Freiburg cohort was used. A summary of all patients used
including IGHVmutation status and BCR expression is given
in Supplementary Table 1. Peripheral bloodmononuclear cells
(PBMCs) fromCLL patients and healthy donors were isolated
by density gradient centrifugation over Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden). Samples were cytometrically
analysed for the quantity of CLL cells and included in this
study if more than 85 % of cells were CD19 positive.
Reagents
Murine monoclonal antibody against CCR7 and CCRL2 and
PE-labelled antibodies against CXCR5 and CXCR3 were pur-
chased from R&D Systems. PE-labelled antibodies against
CXCR4, PE and FITC-labelled antibodies against CD19, and
FITC and PE-labelled antibodies against IgD were purchased
from BD. PE-labelled antibodies against IgM were purchased
from Biolegend and Beckman Coulter. PE-labelled rabbit α-
mouse IgGwas obtained from Dako Cytomation. Goat F(ab’)2
anti-human IgM (α-IgM) and IgD (α-IgD) for stimulations
and F(ab’)2 of irrelevant specificity as a control were purchased
from Southern Biotech. Chemokines were purchased from
Peprotech and R&D. Ibrutinib (PCI-32765) was bought from
Selleckchem, Bafetinib (INNO 406) from Adooq, and R406
from Riegel Pharmaceuticals. Annexin V-FITC and 7-
aminoactinomycin D (7AAD) for determination of cell viabil-
ity were from Beckman Coulter.
BCR stimulation
CLL cells and healthy donor PBMCs were thawed and incu-
bated at 37 °C overnight before use. BCR stimulation was
performed in 48-well plates. Cells were suspended at 4 × 106
cells per ml, 250 μl of the suspension were applied per well,
and α-Ig F(ab’)2 was added at a concentration of 20 μg/ml.
Immobilisation of the F(ab’)2 in wells was performed by di-
lution in PBS and incubation over night at room temperature.
The cell suspension was subsequently added after extensive
washing with PBS and RPMI.
Flow cytometric detection of chemokine receptors
and BCR expression
A total of 2.5 × 105 cells were stained with the appropriate
antibody for 30 min at 4 °C in PBS containing 0.5 % BSA.
Prior to adding the secondary antibody, excess antibody was
removed by washing. A minimum of 2 × 104 cells were mea-
sured by flow cytometry on a FACSCalibur. Viable cells were
identified by SSC-FSC, and the geometric mean of fluores-
cence intensities (MFI) was determined using FlowJo analysis
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software. Mean fluorescence intensity ratios (MFIR) were cal-
culated using the appropriate isotypes.
Intracellular calcium measurement
For measurement of intracellular calcium mobilisation, cells
were prepared as described in Quiroga et al. [20]. A total of
1 × 107 cells were incubated in 1 ml complete RPMI with
4 μMFluo-3-AM (Invitrogen) at 37 °C for 30 min. Cells were
then resuspended at 5 × 106/ml and incubated for another
10 min at 37 °C. After washing in complete RPMI, cells were
resuspended in medium containing 1.5 mMCaCl2 and in case
of the inhibitor studies R406, Bafetinib, or Ibrutinib at a con-
centration of 5 μM. After an incubation of 30 min at 37°, the
cells were put on ice. Five minutes before each measurement,
100 μl of cell suspension was added into 400 μl of prewarmed
RPMI with CaCl2 and, where applicable, with an inhibitor.
After 15 s of baseline acquisition, α-IgM F(ab’)2, α-IgD
F(ab’)2 (10 μg/ml), CXCL13 (500 ng/ml), CCL19, CCL21,
or CXCL12 (200 ng/ml) were added and the fluorescence
intensity was recorded for 2 min. For quantification, the base-
line fluorescence intensity was subtracted from the peak in-
tensity after stimulation. The resulting value was termed
Bcalcium response^.
Chemotaxis
CLL cells were, after 24 h of BCR stimulation, transferred into
transwell inserts (Corning Costar) with 5-μm pores. Either
medium alone or medium containing CXCL12 (100 ng/ml)
or CCL21 (200 ng/ml) was added to the lower well, and the
cells were allowed to migrate for 2 h at 37 °C. Migrated cells
were then stained for CD5/CD19 and counted using Flow
Count Fluorospheres (Beckmann Coulter) as a reference.
Statistical analysis
Calculation of statistical significance was done using Graph
Pad PrismVersion 5.03. After assessing the datasets for normal
distribution, significances were analysed using paired t test in
case of normally distributed samples, and Wilcoxon matched
pairs test in not normally distributed samples. Differences were
considered significant with p < 0.05. P < 0.05 is marked as *,
p < 0.01 as **, and p < 0.001 as ***.
Results
IgM stimulation of CLL cells results in increased calcium
mobilisation in response to IgD
We investigated BCR and chemokine responses upon α-IgM
and α-IgD stimulation in peripheral blood CLL samples.
Analysing IgM and IgD surface expression in a cohort of 36
samples, we found a considerable inter-patient variability.
Except for eight samples harbouring negligible levels of
IgM and IgD on their surface (MFIR = 1), all other samples
displayed clearly detectable IgM and IgD expressions
(Fig. 1a). We did not observe any association of IgM/IgD
expression and the IGHVmutational status in this cohort (data
not shown).
In functional studies, we first evaluated the impact of IgM
or IgD stimulation on further BCR-mediated calcium
mobilisation in CLL samples expressing IgM and IgD. In
agreement with the findings of Mockridge et al. [2], calcium
responses to IgM and IgD stimulation were, like BCR surface
expression, highly variable. Fifty-three percent of investigated
CLL cases showed a very weak or no calcium response to α-
IgM treatment despite detectable surface IgM levels (Fig. 1b,
unstimulated controls). In contrast, the overall response of
CLL cells to stimulation with α-IgD was higher, with only
12 % of cases displaying no calcium flux. As expected,
preincubation withα-IgM orα-IgD resulted in desensitisation
of the prestimulated isotype and thus an abolishment of further
BCR-triggered calcium releases. However, we did not observe
any cross-desensitisation of the other isotypes by IgM or IgD
pre-stimulation. In contrast, the response invoked by α-IgD
administration was significantly reinforced by previous incu-
bation with α-IgM.
IgM stimulation increases IgD expression in CLL but not
healthy donor-derived B cells
The observation of increased IgD-mediated calcium
mobilisation after IgM stimulation raised the question whether
this was caused by modulation of IgD surface expression.
Indeed, increased IgD-mediated calcium mobilisation in
CLL cells upon stimulation with α-IgM was paralleled by a
slight increase in IgD surface expression, while a cross-
desensitisation was observed in healthy B cells, with a reduc-
tion of IgD surface expression after IgM stimulation (Fig. 2a).
In contrast, IgD stimulation reduced IgM expression levels in
CLL as well as healthy B cells (Fig. 2b).
Regulation of chemokine receptor surface expression
and chemokine-induced calcium responses by α-IgM
and α-IgD stimulation is impaired in CLL
The regulation of chemokine receptors is an important process
involved in B cell development and activation. Cases of ag-
gressive CLL are characterised by the massive infiltration of
bone marrow and lymphoid organs, and altered regulation of
homing receptors is involved in disease progression [30].
Therefore, we systematically compared IgM- and IgD-
mediated alterations in chemokine receptor expression in
CLL and normal B cells.
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Fig. 1 IgM- and IgD-mediated
calcium mobilisation in CLL. a
Surface expression of IgM and IgD
was determined by flow cytometry
(n = 36). A logarithmic scale is
used due to the high inter-patient
variation. b CLL cells were
prestimulated by α-IgM or α-IgD
antibodies (20 μg/ml) for 24 h, and
calcium mobilisation upon a sec-
ond BCR stimulation was mea-
sured by flow cytometry (n= 16).
Exemplary fluorescence courses
are given in bii. The arrows indi-
cate the time of stimulation
Fig. 2 Modulation of BCR
surface expression by BCR
activation. a IgD and b IgM
surface expression was measured
by flow cytometry upon BCR
activation by 20 μg/mlα-IgM and
α-IgD antibodies for 24 h, com-
pared to the appropriate negative
control F(ab’)2 in CLL (n = 10)
and healthy B cells (n = 3)
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The extent of downregulation of CXCR4 expression in
CLL by both soluble IgM and IgD stimulation (decrease to
78 and 85 % of the basal expression) was substantially lower
than that observed in healthy donor-derived B cells (decrease
to 20 and 15 % of the basal expression, Fig. 3a). Also, no
significant regulation of CCR7 expression by IgM and IgD
stimulation was observed (Fig. 3b). CXCR5 expression was
significantly reduced upon stimulation of both isotypes in
CLL cells but upregulated by IgM stimulation in healthy
donor-derived B cells (Fig. 3c). Notably, CCRL2 was upreg-
ulated after stimulation of both isotypes in healthy donor-
derived B cells (Fig. 3d), but slightly downregulated in
CLL. Surface expression of the chemokine receptor CXCR3
and the B cell marker CD19 (as a control) were not changed
by stimulation of IgM or IgD on CLL cells under the same
conditions (data not shown).
A stronger BCR stimulus is provided by stimulation with
immobilised antibodies, and next, we tested whether this
could induce a more distinct chemokine receptor regulation.
Indeed, stimulation with immobilised α-IgM significantly re-
duced CXCR4 expression in CLL cells (Fig. 3e). The extent
of downregulation was comparable to that in healthy donor-
derived B cells (to 33 % of the original expression in CLL
cells and to 27 % in healthy B cells). Immobilised α-IgD
exerted no significant effect on CXCR4 expression in CLL,
while in healthy B cells, stimulation of IgM and IgD resulted
in a comparable CXCR4 downregulation. An IgM-induced
reduction of expression was also observed for CXCR5 and
CXCR3 (data not shown).
To assess the impact of IgM and IgD stimulation on the
chemokine receptor system on a more functional basis, we
measured the calcium release induced by chemokines. All
samples tested showed a significant calcium response to the
chemokines CXCL13, CCL19, and CCL21 (Fig. 4).
However, this calcium flux was generally lower than that ob-
served after IgM or IgD stimulation. Moreover, the
chemokine-induced calcium flux could not be altered by prior
IgM or IgD stimulation (Fig. 4).
Chemotaxis towards CXCL12 and CCL21 is differentially
regulated by IgM and IgD activation
In contrast to calcium mobilisation, chemotaxis towards
CXCL12 was significantly reduced upon IgM stimulation
but not affected by IgD stimulation. A double stimulation
did not reduce chemotaxis towards CXCL12 beyond the re-
duction seen after IgM stimulation alone (Fig. 5) and also did
not further decrease CXCR4 expression compared to single
IgM stimulation (data not shown). In contrast, chemotaxis
towards the CCR7 ligand CCL21 was reduced by IgD but
not IgM stimulation. A reduction similar to IgD stimulation
alone was also observed after IgM/IgD double stimulation.
Taken together, while chemokine receptor regulation in
response to stimulation with α-IgM and α-IgD was reduced
in CLL, with compensation when using stronger BCR stimu-
lation by immobilised antigens, differential regulation of
CXCL12- and CCR7-mediated chemotaxis was observed af-
ter IgM and IgD activation.
Inhibition of Syk, Lyn, and Btk strongly reduces
chemokine-induced calcium responses
Using inhibitors against kinases mediating BCR signal-
ling, remarkable effects on the anatomical localisation of
the CLL cells have been observed in clinical trials, possi-
bly by altering chemokine- and integrin-mediated signal
transduction. We thus evaluated the impact of the Lyn/
Abl inhibitor Bafetinib (INNO-406), the Btk inhibitor
Ibrutinib (PCI-32765), and the Syk inhibitor R406 on
BCR- and chemokine-mediated calcium mobilisation.
Samples of ten patients showing a wide range of BCR-
mediated calcium responses were used for this experiment.
In all samples, R406 completely abolished BCR-mediated
calcium release and strongly reduced the responses to the
chemokines CXCL13, CCL19, and CCL21 (Fig. 6).
Bafetinib treatment abolished IgM-mediated calcium re-
lease in all patient samples but one, and IgD-mediated
response in all except for two cases. Responses to all three
chemokines tested were strongly diminished, albeit not
completely abrogated. Ibrutinib prevented calcium release
after IgM and IgD activation in all cases but one (Fig. 6),
also at lower concentrations (Supplementary Fig. 1). It also
considerably reduced chemokine-mediated calcium
mobilisation. Altogether, these therapeutics are highly ef-
fective in abrogating calcium mobilisation after BCR as
well as chemokine receptor activation in the majority of
CLL samples.
Discussion
CLL is a highly environment-dependent tumour with cells
quickly dying when taken into solo cell culture [31]. BCR
activation is a central stimulus driving CLL survival, prolifer-
ation, and pathogenesis [7]. Most CLL cells coexpress IgM
and IgD, yet the ratio is highly variable and patient specific.
The significance of this coexpression and individual func-
tions for each isotype in normal and malignant B cells are
still poorly understood. We thus aimed to determine their
influence onto each other as well as on the chemokine
system. Early papers reported heterologous desensitisation
of IgD function by IgM prestimulation and vice versa in
normal mouse and human B cells [32, 33]. In contrast to
these findings in non-leukemic B cells, we found no
desensitisation of the heterologous isotype in terms of
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calcium signalling or surface expression after selective stimu-
lation of one BCR isotype in CLL. Notably, there was even an
enforcement of IgD-invoked calcium responses by previous
incubation with α-IgM antibodies. This went along with
slightly increased IgD expression, while in healthy B cells a
clear heterologous downmodulation was observed. Similar
observations have previously been made in murine lymphoma
cells [34], indicating that this phenomenon may be intrinsic to
certain types of B cell malignancies. Taking into account the
autonomous BCR signalling in CLL, the increase in calcium
mobilisation and surface expression may reflect the inhibition
of a constitutive internalisation and recycling process by IgM
stimulation, leading to an accumulation of IgD at the cell
surface.
BCR activation fundamentally alters the expression of sev-
eral chemokine receptors on normal B cells in vivo, thereby
assuring their correct localisation during the following steps
of the immune response [35]. Our results confirm the pre-
vious observation of CXCR4 downmodulation in normal B
cells upon IgM engagement [26] and add the observation
of a comparable reduction upon IgD activation in these
cells. In contrast, CLL cells were less susceptible to IgM-
and IgD-induced CXCR4 and CXCR5 regulation than nor-
mal B cells, which may mirror the disrupted architecture
and diffusion of the regular follicular chemokine gradi-
ents in CLL lymphoid organs [36, 37]. Notably, the im-
paired chemokine receptor regulation upon weak soluble
BCR stimulation was independent of the extent of gen-
eral IgM responsiveness and thus not attributable to gen-
eral features of anergy. It was also uncoupled from func-
tional regulation as we observed comparable effects to
the reduction in migration by soluble stimulation to those
reported by Vlad [28] using immobil ised BCR
stimulation.
An interesting novel finding of our study is the differ-
ential influence of IgM versus IgD activation on the che-
motactic preference of CLL cells. IgM-stimulated CLL
cells retained chemotaxis towards the key lymph node che-
mokine CCL21 but displayed downregulated migration to
CXCL12 suggesting a preferential role of CCR7 for migra-
tion of antigen-stimulated CLL cells within the lymphoid
microenvironment. In contrast, the retained chemotaxis to-
wards CXCL12 but not CCL21 upon IgD stimulation may
suggest a different niche preference of these cells. Further
studies should address whether the homing propensities of
CLL cells to distinct organs depend on different IgD/IgM
ratios of these cells.
Finally, we found inhibition of both chemokine- and BCR-
mediated calcium responses by R406, Bafetinib, and
Ibrutinib. While expected for BCR-induced calcium signal-
ling, the strong dependence of chemokine receptor-induced
calcium signals for all three kinases was unanticipated. This
indicates a largely overlapping signalling cascade leading to
the mobilisation of intracellular calcium, which probably
Fig. 4 Calcium mobilisation in response to chemokines. CLL cells (n =
16) were incubated for 24 h with soluble α-IgM or α-IgD antibodies.
Calcium mobilisation was induced by the chemokines CXCL13 (500 ng/
ml), CCL21 (200 ng/ml), and CCL19 (200 ng/ml) and determined using
the Fluo-3 dye as described in materials and methods. The lower panels
show representative examples for the kinetics of Fluo-3 fluorescence. The
arrows indicate the time at which the chemokine was added
Fig. 3 Regulation of chemokine receptors by BCR activation. Surface
expression of a CXCR4, b CCR7, c CXCR5, and d CCRL2 was
measured on CLL (n = 19) and healthy donor-derived (n = 5) B cells after
24-h stimulation with soluble α-IgM and α-IgD (20 μg/ml) antibodies. e
CXCR4 expression after 24-h stimulation with immobilised α-IgM and
α-IgD (20 μg/ml) was assessed on CLL (n = 10) and healthy B cells (n =
4). In all experiments, controls were incubated for the same amount of
time with the appropriate negative control F(ab’)2
R
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converges on the common regulator Plcγ2. Residual Plcγ2
activity upon Lyn or Btk inhibition [38, 39] may account for
intact calcium signals in exceptional patient samples (Fig. 6a)
and could be caused by activating mutations, which should be
addressed in future studies in detail.
Taken together, our data show that in addition to the gen-
erally reduced BCR responsiveness, CLL cells display defects
in the regulation of chemokine receptors after BCR activation,
as well as a specific regulation of migratory preferences by
IgM and IgD.
Fig. 6 Impact of kinase inhibitors on BCR- and chemokine-mediated
calcium mobilisation. Calcium mobilisation of CLL cells in response to
α-IgM (10 μg/ml), α-IgD (10 μg/ml), CXCL13 (500 ng/ml), CCL21
(200 ng/ml), and CCL19 (200 ng/ml) was assessed as described. After
loading with Fluo-3-AM, cells were additionally incubated for 30 min
with 5 μM Bafetinib, Ibrutinib, R406, or an equal volume DMSO as a
control (n = 11)
Fig. 5 Regulation of chemotaxis by BCR activation. Boyden chamber
migration assays were performed towards CXCL12 (100 ng/ml; n = 8)
and CCL21 (200 ng/ml; n = 7) after 24-h stimulation with α-IgM, α-IgD,
or both (10 μg/ml). Cells were allowed to migrate for 2 h and
subsequently stained for CD19/CD5 and for viability using Annexin-V-
FITC and 7AAD. Only Annexin/7AAD double-negative and CD19/CD5
double-positive cells were counted. All experiments were performed as
duplicates; results are shown as the percentage of input cells
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